Matthew S. McKinney, MD, discusses the potential for curative-intent therapies in mantle cell lymphoma.
Matthew S. McKinney, MD, cellular therapy specialist, hematologic oncologist, hematologist (malignant), Duke Cancer Center, Duke Health, discusses the potential for curative-intent therapies in mantle cell lymphoma (MCL).
The treatment of patients MCL has improved significantly in recentyears, McKinney says. However, there is still a long way to go in order to cure patients, McKinney explains. The field is optimistic that, in the future, patients with MCL will have improved treatment options compared with the current standards, McKinney adds.
Moreover, recent studies have shown that with modalities like CAR T-cell therapy could be curative for patients with MCL, McKinney concludes.